A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is
Major finding: The BTK inhibitor ibrutinib is well tolerated and active in B-cell cancers. Approach: The optimal biologic dose of ibrutinib was determined based on BTK active site occupancy. Impact: Inhibition of BTK alone can block active BCR signaling in multiple B-cell malignancies.doi:10.1158/2159-8290.cd-rw2012-178 fatcat:uzc3kpj4jzfidiqz5qw2oce3ca